In the absence of effective T-cell-mediated immune surveillance, Epstein-Barr virus (EBV) behaves as a potent human tumor virus. For example, recipients of solid-organ transplants maintained on immunosuppressive drug regimens manifest dramatically increased risks for developing EBV-associated lymphoproliferative disease or lymphoma (15, 16, 43) . As many as one quarter of recipients of T-cell-depleted allogeneic bone marrow transplants (BMT) develop B-cell lymphomas derived from donor EBV-infected B cells (R. S. Shapiro, A. Chauvenet, W. McGuire, A. Pearson, A. W. Craft, P. McGlave, and A. Filipovich, Letter, N. Engl. J. Med. 318:1334, 1988). Patients with AIDS develop Burkitt's lymphoma, non-Hodgkin's B-cell lymphoma, and central nervous system lymphoma, many of which are EBV related (23) . In addition, children with a variety of congenital T-cell immunodeficiencies are prone to developing fatal lymphoproliferative disease and EBV-related lymphoma (60) .
Adoptive immunotherapy can restore T-cell surveillance that limits the proliferation of EBV-infected B cells in some immunodeficient hosts. Transfers of EBV-specific cytotoxic Tcell lines (CTLs) or lymphocytes of donor origin can arrest EBV lymphoproliferative disease in BMT recipients (17, 29, 41, 42, 57) . Several assay systems have explored the identity of the effector cells active against EBV-transformed B cells. Engraftment of SCID mice with human peripheral blood mononuclear cells (PBMCs) from EBV-seropositive donors (hu-PBL-SCID mice), for example, results in the development of polyclonal EBV-transformed B-cell tumors of human origin, while infusion of T-cell lines raised against EBV-transformed lymphoblastoid cell lines (LCLs) from the donor of the PBMCs can prevent these tumors (6, 7, 27, 36, 44, 46, 50, 56, 59) . These in vivo data together with in vitro experiments indicate that memory T cells are required to regulate outgrowth of EBVassociated lymphomas. However, the crucial T effectors in the protective response are not well characterized.
Many experiments focus on the role of cytotoxic CD8 ϩ T cells in the cell-mediated immune response to EBV. CD8 ϩ T cells make up the majority of "atypical" mononuclear cells characteristic of primary EBV infection, manifested as infectious mononucleosis (2, 68) . CD8 ϩ T cells derived from mononucleosis patients recognize antigenic epitopes of both latent and lytic-cycle EBV proteins (9, 20, 51, 67) . New techniques such as enzyme-linked immunospot assays and fluorescenceactivated cell sorting (FACS) staining with tetrameric major histocompatibility complex (MHC) class I-peptide complexes reveal a surprisingly high frequency of circulating CD8 ϩ T cells specific for individual EBV proteins in healthy seropositive carriers (63) . In vitro stimulation of PBMCs from EBV-seropositive donors with an autologous LCL yields cytotoxic CD8 ϩ , HLA class I-restricted T-cell clones recognizing the same panel of epitopes, which fall predominantly within the EBNA 3A, -B, and -C and LMP2 latency proteins as well as lytic-cycle epitopes such as BZLF1 and BMLF1 (51) . In vivo experiments show that transfer of CD8 ϩ T cells raised against human LCLs can prevent formation of tumors in hu-PBL-SCID mice after infusion of LCLs from the same individual (50) . Virtually all of the published experiments investigating the activity of CD8 ϩ T cells employ fully transformed LCLs expressing the full panel of EBV latent antigens as the antigen-presenting cells and as targets for cytotoxic T cells (9, 26, 50, 54, 67) .
Less is known about the CD4 ϩ , HLA class II-restricted T-cell response to EBV antigens (35) . Until recently, in vitro cocultivation of PBMCs with LCLs yielded rare cytotoxic CD4 ϩ T-cell lines; these CTLs recognized epitopes in the EBNA1 and EBNA2 latent antigens as well as in the BHRF1 lytic antigen (24, 51) . However, new evidence suggests that in vitro exposure to EBNA1-expressing dendritic cells or to LCLs induced to lytic-cycle expression yields CD4
ϩ EBV-reactive cytotoxic T cells (39) . In vivo evidence for CD4 ϩ -mediated EBV-specific activity also exists in hu-PBL-SCID mouse systems. In these mice, CD4
ϩ T-cell lines injected concurrently with LCLs reduce the incidence of lymphoma (50) . Moreover, some T-cell lines effective in human adoptive immunotherapy trials have consisted of 98% CD4 ϩ T cells (17, 40, 57 
MATERIALS AND METHODS

Cultures of PBMCs.
Cell donors were healthy individuals between 19 and 40 years of age whose EBV serologic status was ascertained by standard assays for antibodies to viral capsid antigen and EBNA (14, 32, 49) . Venous blood drawn in a heparin-coated syringe was diluted with 1 volume of RPMI 1640 medium and underlaid with 1 volume of lymphocyte separation medium (Ficoll-Hypaque; ICN). The mixture was centrifuged at 1,000 rpm for 40 min in a clinical centrifuge at room temperature (RT). PBMCs were isolated from the interface of the gradient and resuspended at 10 6 cells/ml in complete RPMI 1640 medium containing 10% heat-inactivated fetal bovine serum (FBS), penicillin, streptomycin, and amphotericin B. Cultures were seeded in 250-l aliquots into 96-well Ubottomed plates for proliferation assays or in 2.5-ml aliquots into flat-bottomed 24-well culture plates (Falcon) for analysis of cell surface markers. Cultures were maintained at 37°C in 5% CO 2 . After 2 weeks, either 100 l or 1 ml of culture volume was replaced with fresh complete medium.
Preparation of stocks of infectious EBV and mock inoculum. Virus stocks were prepared from culture supernatants of the EBV-positive B95-8 cell line (34) . B95-8 cells were seeded at 2 ϫ 10 5 cells/ml in complete RPMI 1640 medium and held for 14 days at 37°C without refeeding. Cells were deposited at 1,500 rpm in a clinical centrifuge. Supernatant fluids harvested at this time contained approximately 10 5 transforming units/ml as measured by immortalization of human umbilical cord lymphocytes. The supernatant was adjusted to contain 10 g of NaCl and 8% (wt/vol) polyethylene glycol (PEG-8000; Sigma) per liter. The precipitate formed after overnight incubation at 4°C was collected by centrifugation at 7,500 rpm in a Sorvall centrifuge with a GS3 rotor. The pellet was resuspended at a ratio of 1 ml of complete medium per 50 ml of starting culture supernatant. Viral stocks were aliquoted and stored at Ϫ70°C. The mock inoculum was prepared in an identical manner from culture supernatant of the EBV-negative B-lymphoma cell line BJAB (25) .
Infection of PBMCs. Cultures were collected onto glass fiber filters using an automated sample harvester (Wallac). Filters were suspended in scintillation fluid, and the incorporated radioactivity was determined with triplicate samples for each experimental condition.
Analysis of cell surface molecules. At intervals after infection or mock inoculation, 2.5-ml aliquots of cells were collected. The number of living cells was determined by trypan blue dye exclusion; viable cells were isolated on a FicollHypaque density gradient. The cells were washed once in phosphate-buffered saline (PBS) and resuspended at 10 6 cells/ml in PBS containing 5% FBS and 0.01% sodium azide. A mixture of saturating concentrations of two different fluorochrome-conjugated mouse monoclonal antibodies against human cell surface molecules was added. These antibodies included anti-CD3-fluorescein isothiocyanate (FITC), anti-CD4-phycoerythrin (PE), anti-CD8-PE, anti-CD16-PE, anti-CD19-Quantum Red, and anti-CD23-FITC. Murine immunoglobulin (Ig) (1 mg/ml) was included in the mixture to inhibit nonspecific binding. The reactivity of antibodies to human lymphoid cell surface molecules was compared to the reactivity of isotype controls consisting of polyclonal murine IgG1-FITC, IgG1-PE, and IgG2-Quantum Red. All antibodies were purchased from Sigma or Dako. Antibodies and cells were incubated together for 45 min on ice. The cells were washed twice in PBS and fixed in 1% paraformaldehyde in PBS. Staining was analyzed on a fluorescence-activated cell sorter (FACS; Becton Dickinson).
Analysis of EBV gene expression. Mixed PBMCs were examined for expression of latent EBNAs by immunofluoresence assays (IFA). PBMCs from cultures infected with EBV 23 days previously and cultured in the presence or absence of FK506 were isolated over a Ficoll-Hypaque gradient and resuspended at 3 ϫ 10 6 cells/ml in PBS. Cells were allowed to air-dry for 25 min at RT on glass slides (PGC Scientifics) and fixed in a 2:1 acetone-methanol solution for 5 min at RT. Slides were stored at Ϫ20°C for up to 1 month. Detection of the latent EBNAs was performed by incubating cells fixed on the slides with a 1:10 dilution of human serum, which had been previously determined to contain antibodies directed against all known EBNAs (58). Cells were washed in PBS and incubated with a 1:16 dilution of freshly frozen EBV-seronegative human serum as a source of complement. Another wash in PBS was followed by incubation with a 1:40 dilution of anti-human complement conjugated to FITC (Atlantic Antibodies/ Incstar). All incubations were performed for 1 h at 37°C. Negative controls consisted of cells reacted with complement and anticomplement-FITC without human serum. Fluorescence was detected under UV illumination with a Zeiss microscope.
Magnetic activated cell sorting. Cells expressing low levels of surface CD23 were separated from those expressing high levels on a magnetic bead column prior to detection of EBNA antigens by indirect IFA. Live PBMCs from cultures infected with EBV for 23 days were harvested over a Ficoll-Hypaque gradient. Cells were incubated with biotinylated anti-human CD23 for 30 min at 4°C in PBS plus 5% bovine serum albumin (BSA). Cells were washed and incubated at 10 ϫ 10 7 cells/ml for 30 min at 4°C in PBS plus 5% BSA with streptavidinconjugated 50-nm-diameter magnetic microbeads (Miltenyi Biotec). Cells were washed and loaded onto a MACS depletion ferromagnetic matrix column (Miltenyi Biotec) set within a magnetic field. Cells with negative or low CD23 expression were isolated using a 24-gauge needle under ambient conditions. Cells with high CD23 expression were recovered by removing the column from the magnetic field and actively plunging the cells through the column. The CD23 low and high fractions were air-dried on separate glass slides. The level of CD23 expression on each of the fractions was verified by costaining with avidin-PE and analysis by FACS.
Analysis of dividing cells. PBMCs isolated on a Ficoll-Hypaque gradient were washed once in PBS and resuspended at 10 7 cells/ml in PBS. They were incubated with 1 M carboxyfluorescein diacetate succinymidyl ester (CFSE; Molecular Probes) for 10 min at 37°C and washed in ice-cold RPMI 1640 plus 10% FBS. CFSE-labeled cells were cultured and infected as described. At intervals after infection, viable cells were isolated on a Ficoll-Hypaque gradient. Lymphocyte cell surface molecules were detected in two steps. In the first step, the cells were incubated with biotinylated anti-CD3, anti-CD4, anti-CD8, anti-CD19, or anti-CD23 antibodies at saturating concentrations for 45 min at 4°C. Anti-CD23-biotin was obtained from Pharmingen. Anti-CD19-biotin was purchased from Dako. All other biotinylated antibodies were purchased from Sigma. Cells were washed in PBS, and in the second step, avidin-PE was added for a 1-h incubation at 4°C. Cells were fixed in 1% paraformaldehyde and analyzed by FACS.
Depletion of lymphocyte and specific T-cell subpopulations. Fresh PBMCs isolated on a Ficoll-Hypaque gradient were resuspended at 2 ϫ 10 7 cells/ml in PBS plus 2% FBS. They were incubated for 30 min at 4°C with magnetic beads conjugated to murine anti-human CD3, anti-CD4, or anti-CD8 antibodies (against T-cell antigens) or to anti-human CD16 antibodies (against a natural killer cell antigen), at the concentrations recommended by the manufacturer (Dynal). Beads and bound cells were removed using magnets (PerSeptive Biosystems). CD14 ϩ CD45 ϩ monocytes were depleted by standard plastic-adherence protocols (11) . The remaining cells were resuspended in complete RPMI 1640, cultured, and infected. The efficiency of depletion was determined immediately after separation by assessment of cell surface molecule expression. In the majority of experiments, less than 1.5% of the remaining final population consisted of cells targeted for depletion.
Isolation of B and T-cell populations by positive selection. PBMCs freshly isolated on a Ficoll-Hypaque gradient were resuspended at 5 ϫ 10 6 to 1 ϫ 10 7 cells/ml in PBS plus 2% FBS, based on suggestions of the magnetic bead manufacturer. Cells were incubated with antibody-conjugated magnetic beads using the conditions employed for negative selection. Anti-human CD4 or anti-CD19 antibody-conjugated beads and bound cells were recovered using magnets and resuspended at 10 8 cells/ml in RPMI 1640 plus 1% FBS. A detachment solution consisting of competing polyclonal goat or sheep antibodies raised against mouse Igs was added, and cells were incubated with gentle agitation for 1 h at RT. CD3 ϩ cells were recovered from the anti-CD3-conjugated beads by incubating the positively selected cell-bead mixture in RPMI 1640 plus 10% FBS at 37°C for at least 6 h, since competing antibodies were not available. Beads were removed by using magnets, and the cells that had been freed from the beads were harvested. The efficiency of isolation of each population was determined immediately after isolation by assessment of cell surface molecule expression. Selected populations were greater than 84.6% pure.
Use of CD23 expression as a marker of B cells activated by EBV. The number of CD19
ϩ CD23 ϩ cells was used as a marker of immune control over EBVinfected B cells when cultures were initiated from mixed PBMC populations (see Fig. 2 ). However, cultures depleted of various T-cell subsets manifest different growth properties regardless of infection by EBV. Therefore, in depleted cultures, the percentages, not numbers, of CD19 ϩ CD23 ϩ cells were used as an indicator of immune control (see Fig. 5 to 7) .
RESULTS
Lack of memory T-cell activity augments proliferation in EBV-infected PBMC cultures from EBV-seropositive individuals.
To analyze the role of T cells and effector mechanisms active in immune surveillance over early stages of EBV infection, we examined the effects of FK506 on EBV-induced lymphoproliferation in vitro. Most previous in vitro studies have monitored PBMC culture responses to EBV via a regression assay, in which the readout is microscopic enumeration of transformed-cell foci after 4 weeks in culture or isolation of transformed lymphoblastoid lines (37, 40) . As a quantitative and rapid assay for T-cell control, we initially assessed cell proliferation in EBV-infected and mock-inoculated PBMC cultures by measuring [ 3 H]dT incorporation 17 to 18 days after inoculation (13, 26, 33, 55) .
Proliferation of infected cells from EBV-seropositive donors was much increased in the presence of FK506, a well-known inhibitor of T-cell activation (10, 12) . In the experiment illustrated in Fig. 1A To determine when T-cell activity impacts EBV-induced lymphoproliferation, kinetic analysis of [ 3 H]dT incorporation in response to EBV infection of PBMC cultures was performed. When the donors of PBMCs were seropositive, the EBV-infected cultures grown in the absence of FK506 proliferated for 7 to 10 days to a level somewhat higher than in mock-infected cultures, but thereafter the proliferation rate declined (Fig. 1C) . In contrast, when the PBMC donors were EBV seronegative, the EBV-infected cultures continued to proliferate and eventually, 15 days after infection, reached the same level of [ 3 H]dT incorporation measured in EBV-infected cultures treated with FK506 (Fig. 1D) . PBMC cultures from all donors infected with EBV in the presence of FK506 displayed progressively increasing proliferative activity to high levels after infection. The proliferation seen in mock-inoculated cultures was not unexpected, as the mock inoculum contains many antigens from FBS and EBV-negative cells which might cause T cells to proliferate. This proliferation was abolished by FK506 treatment (26) . These experiments showed that the ablation of the T-cell response eliminates regression of early proliferation of EBV-infected PBMCs from seropositive donors just as it leads to outgrowth of foci in classical regression assays. This regression of early proliferation is reproducibly manifested 7 to 10 days after infection. This inhibition of proliferation is mediated by memory T cells, since it is not observed in cultures from EBV-seronegative donors.
Memory T-cell activity selectively prevents the outgrowth of EBV-infected proliferating CD23
؉ B cells in PBMC cultures. CD23 has been regularly associated with latent infection and B-cell blast transformation induced by EBV (1, 8, 21, 62) . To determine whether outgrowth of CD23 ϩ cells was selectively inhibited after EBV infection in vitro, we analyzed the numbers and proliferation profiles of T-and B-cell subsets in infected cultures. As illustrated in Fig. 2A , the presence of T-cell activity in PBMCs from seropositive donors dramatically decreased the number of CD23 ϩ B cells seen after EBV infection. By day 17.5 after infection of the FK506-treated cultures, in the absence of T-cell control, CD19 ϩ B cells made up 57% of the population, and notably 37% of lymphocytes were CD23 ϩ B cells. In contrast, by day 17.5, the untreated cultures consisted of 96% T cells, 3.2% CD19 ϩ B cells, and 0.6% CD19 ϩ CD23 ϩ cells. Up to 6.5 days after infection, the untreated and FK506-treated cultures were indistinguishable in expression of lymphocyte surface markers. At this time, both cultures contained a significant number of CD19 ϩ CD23 ϩ B cells, 4.4% of the culture, but these were subsequently eliminated in the presence of T-cell activity in the untreated culture. Although CD23 may also appear on activated CD4
ϩ T cells and follicular dendritic cells as well as activated B cells, in our experiments CD23 expression was not detected on any T-cell populations (data not shown) (5, 38) .
The CD19 ϩ CD23 ϩ cells observed in the absence of T-cell activity are actively proliferating, as demonstrated in Fig. 2B by cells labeled with the fluorescent dye CFSE and cell surface markers. With each cell division, the CFSE dye partitions to daughter cells, and CFSE fluorescence intensity declines by half (28) . At 3 days after infection, there was no difference in fluorescence profile and little cell division was evident between cultures grown in the presence or absence of FK506 (data not shown). In the absence of FK506, by 17.5 days after infection, only a CD3 ϩ T-cell population which had undergone multiple rounds of proliferation remained (Fig. 2B, left panel) . However, in the presence of FK506, the CD19 ϩ and CD23 ϩ populations had undergone more than seven cell divisions, as assessed by intermediate time points where six peaks of proliferation are clearly visible (data not shown) and by dividing the intensity of the nonproliferating peak by 2 7 . The majority of the surviving T cells had not proliferated (Fig. 2B, right  panel) . Division of significant numbers of CD3 ϩ T cells or CD23 ϩ B cells was first noted 6 to 8 days after infection (data not shown).
The CD19 ϩ CD23 ϩ cells which proliferated in the absence of memory T-cell activity expressed latent EBV proteins detected by immunoblotting and anticomplement IFAs (data not shown). At least 75 to 80% of cells present at 23 days after infection with EBV in the presence of FK506 stained brightly for EBNAs, the marker of latent viral infection. Separation of cultures into CD23-low and CD23-high cells showed that the EBNA ϩ cells resided mainly within the CD23-high population ( Table 1) .
Comparison of the number of CD19 ϩ 
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CD23 ϩ B cells was likewise dependent on the cell density at which infected cultures are initiated; this density dependence is a classic feature of the regression phenomenon when assessed by formation of foci of transformed lymphocytes. In cultures derived from EBV-seropositive donors, regression is noted at high starting cell density and is eliminated or reduced at low starting cell densities (31, 52) . It is not known whether this dependence on high cell density reflects a requirement for a critical number of memory T cells per culture, a need for cell-to-cell contact, or other factors such as cytokine concentrations.
We found that inhibition of proliferation assessed by the number of CD19 ϩ CD23 ϩ cells was also dependent on starting cell density (Fig. 3) . By day 16, there were only 3 to 5% CD19 ϩ
CD23
ϩ cells when cultures were initiated at 6 ϫ 10 5 cells/ml or higher in the absence of FK506. However, when cultures were initiated at 2 ϫ 10 5 cells/ml, the cultures contained 44% CD19 ϩ CD23 ϩ cells on day 16. In the presence of FK506, more than 20% of the infected population were CD19 ϩ CD23 ϩ , even if the cells were initially seeded at the highest cell density (10 6 cells/ml). This fraction rose to 44% when the cells were seeded at the lowest cell density; this indicates that even in the presence of FK506, there may be some residual immune activity. Thus, the ability of memory T cells to regulate CD23 cells were crucial in early stages of EBV-specific immune control. As shown in Fig. 4 (Fig. 4A) . Not surprisingly, CD3 ϩ cells were necessary for immune control. There was a slight increase in the percentage of CD23-positive cells in CD3-depleted cultures treated with FK506. This is likely secondary to FK506's ability to block calcineurin-phosphatase activity in cells other than T cells and its ability to enhance B-cell viability (3, 18) .
A rapid increase in the fraction of CD23 ϩ B cells also occurred in EBV-infected cultures depleted of CD4 ϩ cells (Fig.  4B) . Thus, CD4
ϩ cells appeared to be necessary for control over early stages of CD23 ϩ B-cell generation. Surprisingly, regression was maintained in the CD8-depleted cultures, which were indistinguishable from PBMC cultures by CD23 expression 13 days after infection (Fig. 4B) . The addition of FK506 to CD8-depleted cultures eliminated immune control (data not shown). This indicated that CD8 depletion per se was not inhibitory to EBV-induced lymphoproliferation.
Comparison of CD3-depleted, CD4-depleted, and CD8-depleted PBMC cultures derived from a single EBV-seropositive donor confirmed that CD4 ϩ cells were necessary and sufficient to inhibit the accumulation of CD23 ϩ B cells, while CD8 ϩ cells on their own could not (Fig. 4C) CD8-depleted and PBMC cultures are similarly affected by cell density. It was unknown whether CD8-depleted cultures could maintain immune control at initial culture densities lower than 10 6 cells/ml. Figure 5 demonstrates that cultures depleted of more than 97% of CD8 ϩ T cells and cultures of mixed PBMCs inhibit proliferation of CD23 ϩ B cells equally well at various initial culture densities. There were fewer than 10% CD23
ϩ B cells in mixed PBMC and CD8 ϩ T-cell-depleted cultures initiated at the two higher cell densities, 10 6 cells/ml and 2 ϫ 10 5 cells/ml; there was a loss of immune control in both cultures seeded at very low starting cell densities, such as 4 ϫ 10 4 cells/mL. In contrast, when cultures depleted of CD3 ϩ and CD4 ϩ T cells were initiated at all three cell densities, CD23 ϩ B cells represented more than 50% of the cell population at the time of staining. ϩ or CD4 ϩ cell depletion allows rapid appearance and proliferation of CD23 ϩ B cells (Fig. 6 ). At 8.5 days after infection, all cultures contained a low fraction (1.9 to 3.2%) of CD23 ϩ B cells with similar proliferation profiles. After 4 more days (day 12.5), there was a five-to sevenfold increase in the fraction of CD23 ϩ cells in the CD3-and CD4-depleted cultures, with multiple CD23 ϩ cell divisions, as reflected by the large peaks at low fluorescence intensity. During the same interval in PBMC and CD8-depleted cultures, there was little change in the fraction of CD23 ϩ cells or in the CFSE staining profile. CD23 ϩ cells from PBMC and CD8-depleted cultures that did divide did not undergo as many rounds of proliferation as those from CD3-and CD4-depleted cultures. This confirms that the ability to prevent early CD23 ϩ B-cell proliferation is maintained in the absence of CD8 ϩ cells and is particularly manifest between 7 and 12 days after EBV infection in vitro.
Positively selected CD3 ؉ and CD4 ؉ T-cell populations exert control over proliferation of EBV-infected CD23 ؉ B cells. We explored whether purified CD4 ϩ T cells are capable of exerting EBV-specific immune control by adding positively selected T cells to EBV-infected target cells. This was necessary because depletion of CD8 ϩ cells yields a population enriched for CD4 ϩ cells but contains other cells potentially wielding EBV-specific immune activity. In the experiment illustrated in Fig. 7 , the infected target cells were CD3-depleted PBMCs. Addition of increasing numbers of either CD3 ϩ or CD4 ϩ cells to EBV- infected target cells resulted in a decrease in the number of CD23 ϩ B cells remaining at 18 days after infection (Fig. 7) . Positively selected CD3 ϩ cells appeared to be less effective than equal numbers of CD4 ϩ cells. The damping effect of T cells on the number of CD23 ϩ B cells was strongly manifested when 4 ϫ 10 5 or more T cells were added to 2 ϫ 10 5 CD3-depleted cells per ml. This ability of CD4 ϩ T cells to exert control over the fraction of CD23 ϩ B cells present 17 days after EBV infection was also demonstrated when CD19 ϩ cells were infected and used as targets (data not shown).
DISCUSSION
CD4
؉ T cells inhibit EBV-induced B-cell proliferation. In this study we analyzed the capacity of memory T cells to abrogate the proliferation of CD23 ϩ B cells newly infected by EBV. A novel finding of our study is that CD4 ϩ T cells taken directly from the peripheral blood of EBV-seropositive donors contribute significantly to preventing the early stages of EBVinduced lymphoproliferation. In the absence of CD4 ϩ T cells, CD8 ϩ T cells do not inhibit proliferation of CD23 ϩ B cells. In cultures depleted of CD4 ϩ T cells, the fraction of CD23 ϩ B cells increases markedly, and the majority of these cells actively proliferate between days 6 and 12 after EBV infection (Fig. 4B,  4C, and 6 ). This increase in CD23 ϩ B cells does not appear in PBMC cultures or in cultures depleted of CD8 ϩ cells within the first 3 weeks after infection. Even at high initial starting cell densities, such as 10 6 cells/ml, depletion of CD4 ϩ T cells promotes an increase in CD23 ϩ B cells, while depletion of CD8 ϩ cells does not allow outgrowth of CD23 ϩ B cells at the same starting cell density ( Fig. 5 and 6 ). Moreover, after addition to EBV-infected purified target cells, purified CD4 ϩ T cells are sufficient to prevent the outgrowth of CD23 ϩ B cells (Fig. 7) . These experiments suggest that CD4 ϩ T cells themselves act as effectors of regression as well as helpers of a CD8 ϩ T-cellmediated response.
Advances in assessing functional immune control of proliferation. Our conclusions that CD4 ϩ T cells separated from CD8 ϩ T cells are competent to mediate immune control of EBV-induced B-cell activation and proliferation exploit powerful quantitative tools for studying early events following EBV infection. We have employed assays based on proliferation of the total culture ([ 3 H]dT incorporation), the composition of the culture (the number and fraction of CD23 ϩ B cells), and analysis of the number of cells in the culture that have undergone cell division (CFSE dye dilution). All of these assays permit a more accurate, quantitative, and reproducible assessment of the T-cell response to new EBV infection in vitro than does the subjective enumeration of clumps of putatively transformed cells. Moreover, these assays allow monitoring of the kinetic evolution of cell populations responding to EBV infection and indicate the time between 6 and 12 days postinfec- tion as the time of major T-cell expansion and activity (Fig. 3 , 5, and 7).
Similarities of findings in assays based on CD23
؉ B-cell proliferation and morphologic changes. Our assays, which enumerate CD23 ϩ B cells within the first 2 to 3 weeks after EBV infection, may not measure the same events as the classical regression assay. Nonetheless, our quantitative assay system reproduces many of the findings of the classical regression assay, in which foci of transformed cells are counted under a microscope. Both assays show that (i) immune surveillance occurs only when target cells for EBV infection are obtained from EBV-seropositive individuals (Fig. 1), (ii) T cells are necessary to prevent outgrowth, and inclusion of a T-cell immunosuppressant, such as FK506, blocks the capacity of memory T cells to mediate immune surveillance ( Fig. 1 to 4) , and (iii) immune surveillance over EBV-induced lymphoproliferation in cultures derived from EBV-seropositive individuals is exquisitely sensitive to the density at which the culture was initiated ( Fig. 3 and 5 ) (53). These observations are consistent hallmarks of the regression phenomenon. Thus, our CD23 ϩ B-cell assay could yield quantitative assessment of patient immune status in clinical disease states, just as classical regression assays have been used to gauge the vigor of cell-mediated immunity to EBV in immunocompromised patients (70) . Preliminary results indicate that our assay based on CD23 ϩ B-cell proliferation can be used to monitor the acquisition of effective T-cell surveillance after primary EBV infection manifested clinically as infectious mononucleosis (data not shown).
Reconciliation of CD4 ؉ T-cell activity with published cytotoxic activity of CD8 ؉ T cells against EBV-infected targets.
That CD4
ϩ T cells can act as both cytotoxic effectors and immune helpers and thus play a significant role in preventing early proliferation of activated CD23
ϩ EBV-infected lymphoblasts does not preclude contributions to immunosurveillance by other immune cells, including CD8 ϩ T cells. Our data show that CD8 ϩ T cells by themselves, in the absence of CD4 ϩ T cells, are unable to prevent CD23 ϩ B cell proliferation in the 2 to 3 weeks following EBV infection in vitro. However, it is likely that CD8 ϩ T cells are active in the presence of CD4 ϩ T cell help, and our experiments do not rule out such activity in a primary mixed PBMC culture. There is no question that CD8 ϩ T cells are highly reactive and cytotoxic towards EBVtransformed LCLs (9, 20, 51, 67) . In fact, HLA class I-restricted (putatively CD8 ϩ ) T cells have been isolated from cultures in the process of regression and shown to inhibit the growth of already established LCLs (54) . However, this experiment does not address whether these same T cells are responsible for inducing regression in the primary cultures. Our experiments investigate the nature of the immune response in regulating B cells in the early stages of EBV infection and transformation, not the immune response of CTLs to immortalized LCLs. Newly infected B cells and fully transformed LCLs are different targets for cell-mediated immunity. Newly infected cells undergoing EBV-induced proliferation likely express different cellular and viral antigens than already immortalized cells and may be subject to surveillance by different types of T cells (64) . The design of our experimental system, in terms of the nature of the EBV-infected targets, the initial resting state of the fresh memory T cells, the time of analysis, and the CD23 ϩ B-cell readout, differs from those of assays used previously. Thus, our findings on the role of CD4 ϩ T cells do not contradict the established ability of CD8 ϩ T cells to exert immune surveillance over EBV infection. Both types of T cells appear to be important.
Increasing evidence for the role of CD4 ؉ T cells in EBV and other viral infections. In summary, our work using a physiologically relevant, functional, in vitro assay system solidifies the role of CD4 ϩ T cells in an in vitro EBV-specific immune response. Quantitative tools to analyze this role have farreaching implications, because CD4
ϩ CTLs can recognize both latent and lytic-cycle antigens and can be generated from both naive and memory populations (19, 51, 61) . While the antigenic targets have not yet been identified, reactivation of lytic virus in LCLs can generate a CD4-dominated rather than a CD8-dominated CTL response (69) . However, CD4
ϩ CTL are not restricted to lytic-cycle antigens, since Munz et al. have found that EBNA1, a latent EBV protein which is poorly recognized by CD8 ϩ CTL because of impaired MHC class I loading of EBNA1, is particularly important in the CD4 ϩ CTL response (4, 39) . CD4
ϩ CTLs can act through perforin-mediated cytotoxicity or via a Fas-Fas ligand-mediated pathway (19, 69) . Our study leaves open the possibility that EBV-specific CD4
ϩ T cells may function by a cytolytic or an antiproliferative mechanism. Specifically, preliminary studies indicate that gamma interferon is preferentially produced by CD4 ϩ cells in the presence of virus versus the presence of a mock inoculum. Other preliminary findings indicate that two clones of EBNA1-specific CD4
ϩ CTLs which secrete gamma interferon also inhibit CD23
ϩ B-cell outgrowth in our assay. Moreover, CD4 ϩ T cells have been found to exert a protective effect in vivo following infection by respiratory syncytial virus, lymphocytic choriomeningitis virus, and herpes simplex virus in mice (30, 45, 66) . Thus, the CD4 ϩ T-cell-mediated inhibition of EBV-induced proliferation demonstrated here may prove a crucial component of the in vivo immune response to EBV.
